Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evolving treatment of advanced colorectal cancer.

Literature DB >> 20425074

Evolving treatment of advanced colorectal cancer.

Abstract

Advances in colorectal cancer treatment have led to improved outcomes for patients. A number of cytotoxic agents, alone and in combination, have shown activity. The addition of the newer, so-called "targeted" agents to standard chemotherapy drugs and regimens has also modestly improved outcomes. Progress in our knowledge and understanding of molecular pathways has led to the identification of markers critical in determining response or nonresponse to some of the targeted agents. This review discusses the available therapies in metastatic colorectal cancer and describes some of the molecular markers implicated in activity and resistance to current targeted therapies.

Entities: Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20425074 DOI： 10.1007/s11912-010-0096-1

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

28 in total

Review 1. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.

Authors: E Ramsay Camp; Justin Summy; Todd W Bauer; Wenbiao Liu; Gary E Gallick; Lee M Ellis
Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531

2. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

4. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Authors: C-H Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; D Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; E Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem
Journal: Ann Oncol Date: 2007-12-06 Impact factor: 32.976

5. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors: Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544

Review 6. Epithelial growth factor receptor interacting agents.

Authors: Jose Baselga; Joan Albanell
Journal: Hematol Oncol Clin North Am Date: 2002-10 Impact factor: 3.722

7. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors: Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544

8. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544

9. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Authors: Eduardo Díaz-Rubio; Jose Tabernero; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Alberto Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Journal: J Clin Oncol Date: 2007-06-04 Impact factor: 44.544

10. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors: Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal: Lancet Date: 2007-07-14 Impact factor: 79.321

8 in total

1. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

Authors: Sang Joon Shin; Joong Bae Ahn; Kyung Soo Park; Yoon Jung Lee; Yong Sang Hong; Tae Won Kim; Hye Ryun Kim; Sun Young Rha; Jae Kyung Roh; Dal-Hyun Kim; Chin Kim; Hyun Cheol Chung
Journal: Invest New Drugs Date: 2010-12-29 Impact factor: 3.850

Review 2. Personalized colon cancer care in 2010.

Authors: Daniel V T Catenacci; Mark Kozloff; Hedy L Kindler; Blase Polite
Journal: Semin Oncol Date: 2011-04 Impact factor: 4.929

Review 3. Personalizing medicine for metastatic colorectal cancer: current developments.

Authors: Andrea Marin Marques; Alice Turner; Ramon Andrade de Mello
Journal: World J Gastroenterol Date: 2014-08-14 Impact factor: 5.742

4. OncoKB: A Precision Oncology Knowledge Base.

Authors: Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz
Journal: JCO Precis Oncol Date: 2017-05-16

5. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Authors: Jeffrey A Meyerhardt; Marek Ancukiewicz; Thomas A Abrams; Deborah Schrag; Peter C Enzinger; Jennifer A Chan; Matthew H Kulke; Brian M Wolpin; Michael Goldstein; Lawrence Blaszkowsky; Andrew X Zhu; Meaghan Elliott; Eileen Regan; Rakesh K Jain; Dan G Duda
Journal: PLoS One Date: 2012-06-12 Impact factor: 3.240